Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment
Open Access
- 22 June 2020
- journal article
- letter
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 59 (8) , 2171-2173
Abstract
Rheumatology key messageAnakinra as a sole treatment may be useful in the immune-mediated hyperinflammatory phase of COVID-19.Keywords
This publication has 10 references indexed in Scilit:
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, ChinaJAMA Internal Medicine, 2020
- Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical GuideFrontiers in Immunology, 2020
- Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-192020
- Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation SyndromeACR Open Rheumatology, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies.JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- The Immunology of Macrophage Activation SyndromeFrontiers in Immunology, 2019
- Successful Tocilizumab Therapy for Macrophage Activation Syndrome Associated with Adult-Onset Still’s Disease: A Case-Based ReviewCase Reports in Medicine, 2016
- Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation SyndromeCritical Care Medicine, 2016